coherus biosciences  wikipedia coherus biosciences from wikipedia the free encyclopedia   redirected from coherus biosciences jump to navigation search this article may have been created or substantially edited in return for undisclosed payments a violation of wikipedias terms of use its neutrality may be compromised as a result it may require cleanup to comply with wikipedias content policies particularly neutral point of view and sourcing please discuss further on the talk page july  learn how and when to remove this template message coherus biosciences inc industry biopharmaceutical founded  headquarters redwood city california united states key people dennis m lanfear president ceo  chairman website wwwcoheruscom coherus biosciences is an american biopharmaceutical company focused on developing and commercializing biosimilar drugs contents  history  business model  awards  references historyedit coherus biosciences was founded in  as a pureplay biosimilar company with headquarters in redwood city california the company is publicly traded on the nasdaq stock market with the tag nasdaqchrs business modeledit coherus develops a type of biologic products called biosimilars awardsedit   deloitte’s technology fast  award referencesedit  judy judy packertursman  january  coherus sticks to  timeline for humira biosimilar biopharmadivecom retrieved  january    coherus offers positive phase iii data on humira biosimilar zackscom  january  retrieved  january    teresa graham  january  blackrock advisors llc has  stake in coherus biosciences inc chrs thecerbatgemcom retrieved  january    enbrel biosimilar biotech coherus biosciences sets terms for  million ipo renaissancecapitalcom  october  retrieved  january    diana ernst  october  neulasta biosimilar to be reviewed by fda emprcom retrieved  january    jessica moore  january  coherus biosciences inc chrs shares sold by tiaa cref investment management llc thecerbatgemcom retrieved  january    coherus biosciences inc nasdaqchrs moderate sell ratings at  themarketsdailycom  january  retrieved  january    speed of peninsula biotechs potential blockbuster drug rests with supreme court bizjournalscom  january  retrieved  january    daniel jordon  january  coherus biosciences inc chrs receives average rating of “buy” from brokerages sportsperspectivescom retrieved  january     technology fast  pdf deloittecom retrieved  january   retrieved from httpsenwikipediaorgwindexphptitlecoherusbiosciencesoldid categories pharmaceutical companies of the united statescompanies established in health care companies based in californiahidden categories wikipedia articles with undisclosed paid content from july  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view coherus biosciences  wikipedia coherus biosciences from wikipedia the free encyclopedia   redirected from coherus biosciences jump to navigation search this article may have been created or substantially edited in return for undisclosed payments a violation of wikipedias terms of use its neutrality may be compromised as a result it may require cleanup to comply with wikipedias content policies particularly neutral point of view and sourcing please discuss further on the talk page july  learn how and when to remove this template message coherus biosciences inc industry biopharmaceutical founded  headquarters redwood city california united states key people dennis m lanfear president ceo  chairman website wwwcoheruscom coherus biosciences is an american biopharmaceutical company focused on developing and commercializing biosimilar drugs contents  history  business model  awards  references historyedit coherus biosciences was founded in  as a pureplay biosimilar company with headquarters in redwood city california the company is publicly traded on the nasdaq stock market with the tag nasdaqchrs business modeledit coherus develops a type of biologic products called biosimilars awardsedit   deloitte’s technology fast  award referencesedit  judy judy packertursman  january  coherus sticks to  timeline for humira biosimilar biopharmadivecom retrieved  january    coherus offers positive phase iii data on humira biosimilar zackscom  january  retrieved  january    teresa graham  january  blackrock advisors llc has  stake in coherus biosciences inc chrs thecerbatgemcom retrieved  january    enbrel biosimilar biotech coherus biosciences sets terms for  million ipo renaissancecapitalcom  october  retrieved  january    diana ernst  october  neulasta biosimilar to be reviewed by fda emprcom retrieved  january    jessica moore  january  coherus biosciences inc chrs shares sold by tiaa cref investment management llc thecerbatgemcom retrieved  january    coherus biosciences inc nasdaqchrs moderate sell ratings at  themarketsdailycom  january  retrieved  january    speed of peninsula biotechs potential blockbuster drug rests with supreme court bizjournalscom  january  retrieved  january    daniel jordon  january  coherus biosciences inc chrs receives average rating of “buy” from brokerages sportsperspectivescom retrieved  january     technology fast  pdf deloittecom retrieved  january   retrieved from httpsenwikipediaorgwindexphptitlecoherusbiosciencesoldid categories pharmaceutical companies of the united statescompanies established in health care companies based in californiahidden categories wikipedia articles with undisclosed paid content from july  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view coherus biosciences inc nasdaqchrs quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancecoherus biosciences incnasdaqchrsadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   coherus biosciences inc  public nasdaqchrs   watch this stock      after hours    jul  pm edt   nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg  mkt cap m pe      divyield      eps  shares m beta      inst own  news relevance date all news for coherus biosciences inc » subscribe advertisement events add chrs to my calendars aug   q  coherus biosciences inc earnings call  pm edt  aug   q  coherus biosciences inc earnings release  pm edt  jun   coherus biosciences inc conference call to discuss fdas issuance of complete response letter for its biologics license application  may   coherus biosciences inc at bank of america merrill lynch healthcare conference  may   coherus biosciences inc annual shareholders meeting may   q  coherus biosciences inc earnings call  may   q  coherus biosciences inc earnings release may   coherus biosciences inc at deutsche bank health care conference  more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  twin dolphin dr ste redwood city ca united states  map phone fax website links httpwwwcoheruscom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry bio therapeutic drugs more from factset » description coherus biosciences inc is a latestage clinical biologics platform company the company is engaged in the business of developing and commercializing biosimilar products the companys business is organized around therapeutic franchises including oncology biosimilar candidates pegfilgrastim neulasta and bevacizumab avastin immunology antitnf biosimilar candidates etanercept enbrel and adalimumab humira ophthalmology biosimilar candidate ranibizumab lucentis and multiple sclerosis small molecule therapeutic candidate chs the companys product candidate pipeline includes chs chs chs chs and chs its chs is a granulocyte colonystimulating factor gcsf product candidate its bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor a vegfa its etanercept enbrel is the reference product for chs more from reuters » officers and directors dennis m lanfear chairman of the board president chief executive officer age  bio  compensation   reuters jeanfrederic viret phd chief financial officer age  bio  compensation   reuters peter k watler chief technology officer age  bio  compensation   reuters alan c herman phd chief scientific officer age  bio  compensation   reuters barbara k finck md chief medical officer age  bio  compensation   reuters mats wahlstrom lead independent director age  bio  compensation   reuters christos richards director age  bio  compensation   reuters august j troendle md director age  bio  compensation   reuters james i healy md phd independent director age  bio  compensation   reuters v bryan lawlis jr phd independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service chrs key statistics  coherus biosciences inc financial ratios  marketwatch bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close coherus biosciences inc nasdaq chrs go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus coherus biosciences inc after hours  quotes are delayed by  min jul    pm chrs quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description coherus biosciences inc is a latestage clinical biologics platform company which engages in the development and commercializition of biosimilar therapeutics worldwide it focuses on global biosimilar market the company was founded by dennis m lanfear stuart e builder dr alan herman doug f coherus biosciences inc is a latestage clinical biologics platform company which engages in the development and commercializition of biosimilar therapeutics worldwide it focuses on global biosimilar market the company was founded by dennis m lanfear stuart e builder dr alan herman doug farrar and steve glover in september  and is headquartered in redwood city ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr denny m lanfear   chairman president  chief executive officer dr jeanfrédéric viret   chief financial officer dr alan c herman   chief scientific officer dr barbara k finck   chief medical officer dr peter k watler   chief technical officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  alan c herman chief scientific officer    disposition at  per share   alan c herman chief scientific officer    disposition at  per share   alan c herman chief scientific officer    disposition at  per share   mats wahlström director      mats wahlström director      alan c herman chief scientific officer    disposition at  per share   alan c herman chief scientific officer    disposition at  per share   alan c herman chief scientific officer    disposition at  per share   mats wahlström director      mats wahlström director      alan c herman chief scientific officer    disposition at  per share   jeanfrédéric viret chief financial officer    disposition at  per share   jeanfrédéric viret chief financial officer    derivativenonderivative trans at  per share   alan c herman chief scientific officer    disposition at  per share   alan c herman chief scientific officer    disposition at  per share  newslatestcompanyuschrs marketwatch news on chrs coherus biosciences stock drops  after fda fails to approve drug  pm june    emma court coherus biosciences stock drops  after drug wasnt approved by fda  am june    emma court these drugs could cut american health costs by  billion if only we could take them  am july    emma court why amgen’s positive biosimilar news isn’t as good as it seems  pm july    emma court coherus biosciences started at outperform with  stock price target at credit suisse  am jan    tomi kilgore these are the most profitable nasdaq biotech companies  pm march    philip van doorn newsnonmarketwatchcompanyuschrs other news on chrs roundtable  underdog stock im watching  am july    motley fool  dividend stocks in healthcare  pm july    motley fool heres whats behind amgen incs  gain in june  am july    motley fool  things in biotech you should learn today july    am july    seeking alpha coherus biosciences has few more prospects in its arsenal  pm july    seeking alpha coherus restructures after fda rejects marketing application for neulasta biosimilar  of workforce axed  pm june    seeking alpha abbvie abbv stock hits week high more room to run  am june    zackscom abbvie stock just hit a week high heres why it should go even higher  am june    motley fool  growth stocks for savvy investors  am june    motley fool the supreme court just made a big opportunity for biosimilars even bigger  pm june    motley fool snippet roundup novartis enters advair generic race biogen dealt cfo blow  pm june    seeking alpha  incredibly cheap biotech stocks  pm june    motley fool  stocks that could double your money  am june    motley fool coherus biosimilar knockback gives amgen neulasta on life  pm june    seeking alpha coherus biosciences inc chrs hits ‘speed bump’ for chs maxim remains positive  am june    smarteranalyst coherus stock plummets as fda rejects neulasta biosimilar  am june    zackscom  things in biotech you should learn today june    am june    seeking alpha why pandora media coherus biosciences and erin energy slumped today  pm june    motley fool analysts still bullish on coherus despite crl on chs  pm june    seeking alpha coherus dives to yearlow after amgenrivaling drug sees delay  am june    investors business daily loading more headlines at a glance coherus biosciences inc  twin dolphin drive suite  redwood city california  phone   industry  sector  fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for chrs newspressreleasecompanyuschrs press releases on chrs coherus biosciences to report second quarter  financial results on august th  am july    globenewswire todays research reports on stocks to watch coherus biosciences and omeros corporation  am june    accesswire covered call reports for amazoncom coherus biosciences d systems the kroger co and tesla motors include trade ideas that offer returns of  or more  am june    pr newswire  prf coherus biosciences receives complete response letter from fda for its biologics license application for chs pegfilgrastim biosimilar candidate  am june    globenewswire coherus biosciences management to present at th nasdaq omx investor program  am june    globenewswire research reports coverage on biotech stocks  achaogen bellicum pharma coherus biosciences and conatus pharma  am june    pr newswire  prf coherus biosciences prevails in  ipr decision  pm may    globenewswire coherus biosciences reports first quarter  corporate highlights and financial results  pm may    globenewswire investor network coherus biosciences inc to host earnings call  am may    accesswire coherus biosciences management to present at two investor healthcare conferences in may  am may    globenewswire research reports coverage on biotech stocks  ultragenyx pharma chimerix coherus biosciences and omeros  am april    pr newswire  prf coherus biosciences completes patent dance exchange with amgen for neulasta biosimilar  am april    globenewswire coherus biosciences to report first quarter  financial results on may th  am april    globenewswire coherus biosciences appoints erik wiberg as executive vice president of corporate development  pm march    globenewswire coherus biosciences reports fourth quarter and full year  corporate highlights and financial results  pm march    globenewswire coherus addresses trade secret action filed by amgen  am march    globenewswire statement by coherus ceo regarding biosimilars user fees  pm march    globenewswire coherus announces chs pharmacokinetic clinical bioequivalence study meets primary endpoint  am march    globenewswire coherus biosciences management to present at two investor healthcare conferences in march  am march    globenewswire coherus biosciences to report fourth quarter and full year  financial results on march th  pm feb    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abritishmade seedlip aims to woo the nondrinking crowd aset yourself up to get the most out of retirement aeuropean stocks sell off as ubs falls tech worries weigh aprince william and kate middleton are hiring— though not for these weird five royal family jobs arightmove profit rises on ad sales abank of ireland profit falls to restart dividend ahow do i get a reverse mortgage aus tech stocks shape up for another day of selling after amazon disappoints athis city’s subway system will soon run entirely on renewable energy a‘skinny’ repeal of obamacare fails to pass in latenight senate vote aubs credit suisse profit up after strategic shift arenault firsthalf profit leaps on higher volume aftse  under pressure as bt pushed lower afrances cac  falls  dropping further in early friday trade abarclays falls  after earnings report abritish airways parent iag rises  after quarterly profit report abritish airways parent iags profit soars agermanys dax opens  lower at  afrances cac  opens  lower at  alinde profit slides on restructuring costs loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  coherus biosciences  wikipedia coherus biosciences from wikipedia the free encyclopedia   redirected from coherus biosciences jump to navigation search this article may have been created or substantially edited in return for undisclosed payments a violation of wikipedias terms of use its neutrality may be compromised as a result it may require cleanup to comply with wikipedias content policies particularly neutral point of view and sourcing please discuss further on the talk page july  learn how and when to remove this template message coherus biosciences inc industry biopharmaceutical founded  headquarters redwood city california united states key people dennis m lanfear president ceo  chairman website wwwcoheruscom coherus biosciences is an american biopharmaceutical company focused on developing and commercializing biosimilar drugs contents  history  business model  awards  references historyedit coherus biosciences was founded in  as a pureplay biosimilar company with headquarters in redwood city california the company is publicly traded on the nasdaq stock market with the tag nasdaqchrs business modeledit coherus develops a type of biologic products called biosimilars awardsedit   deloitte’s technology fast  award referencesedit  judy judy packertursman  january  coherus sticks to  timeline for humira biosimilar biopharmadivecom retrieved  january    coherus offers positive phase iii data on humira biosimilar zackscom  january  retrieved  january    teresa graham  january  blackrock advisors llc has  stake in coherus biosciences inc chrs thecerbatgemcom retrieved  january    enbrel biosimilar biotech coherus biosciences sets terms for  million ipo renaissancecapitalcom  october  retrieved  january    diana ernst  october  neulasta biosimilar to be reviewed by fda emprcom retrieved  january    jessica moore  january  coherus biosciences inc chrs shares sold by tiaa cref investment management llc thecerbatgemcom retrieved  january    coherus biosciences inc nasdaqchrs moderate sell ratings at  themarketsdailycom  january  retrieved  january    speed of peninsula biotechs potential blockbuster drug rests with supreme court bizjournalscom  january  retrieved  january    daniel jordon  january  coherus biosciences inc chrs receives average rating of “buy” from brokerages sportsperspectivescom retrieved  january     technology fast  pdf deloittecom retrieved  january   retrieved from httpsenwikipediaorgwindexphptitlecoherusbiosciencesoldid categories pharmaceutical companies of the united statescompanies established in health care companies based in californiahidden categories wikipedia articles with undisclosed paid content from july  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view coherus biosciences  wikipedia coherus biosciences from wikipedia the free encyclopedia   redirected from coherus biosciences jump to navigation search this article may have been created or substantially edited in return for undisclosed payments a violation of wikipedias terms of use its neutrality may be compromised as a result it may require cleanup to comply with wikipedias content policies particularly neutral point of view and sourcing please discuss further on the talk page july  learn how and when to remove this template message coherus biosciences inc industry biopharmaceutical founded  headquarters redwood city california united states key people dennis m lanfear president ceo  chairman website wwwcoheruscom coherus biosciences is an american biopharmaceutical company focused on developing and commercializing biosimilar drugs contents  history  business model  awards  references historyedit coherus biosciences was founded in  as a pureplay biosimilar company with headquarters in redwood city california the company is publicly traded on the nasdaq stock market with the tag nasdaqchrs business modeledit coherus develops a type of biologic products called biosimilars awardsedit   deloitte’s technology fast  award referencesedit  judy judy packertursman  january  coherus sticks to  timeline for humira biosimilar biopharmadivecom retrieved  january    coherus offers positive phase iii data on humira biosimilar zackscom  january  retrieved  january    teresa graham  january  blackrock advisors llc has  stake in coherus biosciences inc chrs thecerbatgemcom retrieved  january    enbrel biosimilar biotech coherus biosciences sets terms for  million ipo renaissancecapitalcom  october  retrieved  january    diana ernst  october  neulasta biosimilar to be reviewed by fda emprcom retrieved  january    jessica moore  january  coherus biosciences inc chrs shares sold by tiaa cref investment management llc thecerbatgemcom retrieved  january    coherus biosciences inc nasdaqchrs moderate sell ratings at  themarketsdailycom  january  retrieved  january    speed of peninsula biotechs potential blockbuster drug rests with supreme court bizjournalscom  january  retrieved  january    daniel jordon  january  coherus biosciences inc chrs receives average rating of “buy” from brokerages sportsperspectivescom retrieved  january     technology fast  pdf deloittecom retrieved  january   retrieved from httpsenwikipediaorgwindexphptitlecoherusbiosciencesoldid categories pharmaceutical companies of the united statescompanies established in health care companies based in californiahidden categories wikipedia articles with undisclosed paid content from july  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view coherus biosciences inc private company information  bloomberg july    am et biotechnology company overview of coherus biosciences inc snapshot people company overview coherus biosciences inc a latestage clinical biologics platform company focuses on developing and commercializing biosimilar products worldwide the company’s product candidates include chs a pegfilgrastim biosimilar candidate which is used for the treatment of febrile neutropenia chs an etanercept biosimilar candidate which is in various phases of clinical trials for the treatment of ankylosing spondylitis juvenile idiopathic arthritis psoriatic arthritis rheumatoid arthritis and psoriasis and chs a bevacizumab biosimilar candidate which is in preclinical stage for the treatment of metastatic colorectal cancer non–small cell lung cancer metastatic kidney ca coherus biosciences inc a latestage clinical biologics platform company focuses on developing and commercializing biosimilar products worldwide the company’s product candidates include chs a pegfilgrastim biosimilar candidate which is used for the treatment of febrile neutropenia chs an etanercept biosimilar candidate which is in various phases of clinical trials for the treatment of ankylosing spondylitis juvenile idiopathic arthritis psoriatic arthritis rheumatoid arthritis and psoriasis and chs a bevacizumab biosimilar candidate which is in preclinical stage for the treatment of metastatic colorectal cancer non–small cell lung cancer metastatic kidney cancer advanced cervical cancer platinumresistant ovarian cancer and recurrent glioblastoma its product candidates also comprise chs an adalimumab biosimilar candidate which is in various phases of clinical trials to treat ankylosing spondylitis behçets disease crohn’s disease juvenile idiopathic arthritis psoriasis psoriatic arthritis rheumatoid arthritis and ulcerative colitis and chs a ranibizumab biosimilar candidate which is in preclinical stage for the treatment of neovascular wet agerelated macular degeneration macular edema following retinal vein occlusion diabetic macular edema and diabetic retinopathy coherus biosciences inc has license agreement with daiichi sankyo company limited baxalta incorporated baxalta us inc and baxalta gmbh genentech inc and selexis sa the company was formerly known as biogenerics inc and changed its name to coherus biosciences inc in april  coherus biosciences inc was founded in  and is headquartered in redwood city california detailed description  twin dolphin drivesuite redwood city ca united statesfounded in  employees phone  wwwcoheruscom key executives for coherus biosciences inc mr dennis m lanfear chairman chief executive officer and president age  total annual compensation k dr jeanfrédéric viret phd chief financial officer age  total annual compensation k dr barbara k finck md chief medical officer age  total annual compensation k dr peter k watler phd chief technical officer age  total annual compensation k dr alan c herman phd chief scientific officer age  total annual compensation k compensation as of fiscal year  coherus biosciences inc key developments coherus biosciences receives complete response letter from fda jun   coherus biosciences inc announced that the us food and drug administration has issued a complete response letter for its biologics license application bla for chs a pegfilgrastim neulasta biosimilar candidate under the k pathway the crl primarily focused on the fda request for a reanalysis of a subset of subject samples with a revised immunogenicity assay and requests for certain additional manufacturing related process information the fda did not request a clinical study to be performed in oncology patients additionally the crl does not indicate additional process qualification lots would be required or raise concerns over the gmp status of chs bulk manufacturing and fillfinish vendors coherus biosciences inc  special call jun   to discuss fda feedback coherus biosciences inc presents at nasdaq th investor program jun  am jun   coherus biosciences inc presents at nasdaq th investor program jun  am venue the may fair hotel stratton st mayfair london united kingdom similar private companies by industry company name region n labs inc united states andme inc united states c tech corporation inc united states v biosciences inc united states bar biologics inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact coherus biosciences inc please visit wwwcoheruscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close contact us  coherus biosciences  a biosimilar therapeutics developer about coherus the frontier of biosimilars our scientific platform our products investors join our team ≡ about coherus the frontier of biosimilars our scientific platform our products investors join our team contact us to learn more about coherus biosciences call us or send us a letter address  twin dolphin drive suite  redwood city ca  phone    the future of biosimilars is today there are tremendous investment opportunities in this rapidly growing market learn more about our products privacy policy site map contact us join our team copyright   coherus biosciences coherus biosciences inc nasdaqchrs coherus biosciences inc chrs product news news  stocknewscom     follow us stocktwits twitter coherus biosciences inc chrs product news news chrs – daiichi sankyo to discontinue development of coherus’ etanercept biosimilar product candidate in japan and to conclude the parties’ global openlabel safety extension study in rheumatoid arthritis jul    pm  by stocknewscom staff product news key facts surrounding this news item chrs had a powr rating of d sell coming into today chrs was  below its day moving average coming into today chrs was  below its day moving average coming into today chrs was  below its day moving average coming into today chrs was  below its day moving average coming into today chrs was  below its day moving average coming into today chrs had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about coherus biosciences inc chrs coherus biosciences is a pureplay biosimilar platform company that develops and commercializes highquality therapeutics for major regulated markets the company was founded in  and is based in redwood city california view our full chrs ticker page with ratings news and more chrs at a glance chrs current powr rating™ overall powr rating™ chrs current price   more chrs ratings data and news chrs price reaction the day of this event jul  chrs closing price chrs volume from avgleading up to this eventchrs mo returnafter this eventchrs day returnchrs day returnchrs day return chrs price chart more coherus biosciences inc chrs news view all eventdate symbol news detail start price end price change powr rating loading please wait view all chrs news page generated in  seconds bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one ﻿ coherus biosciences chrs receiving somewhat positive news coverage analysis finds  markets daily daily ratings  news for coherus biosciences inc complete the form below to receive the latest headlines and analysts recommendationsfor coherus biosciences inc with our free daily email newsletter follow themarketsdaily the markets daily recent posts tradewinds capital management llc has  stake in abbott laboratories nyseabt bank of new york mellon corp lowers position in resolute energy corporation ren moloney securities asset management llc purchases  shares of att inc nyset cisco systems inc csco position boosted by wealthtrust axiom llc morgan stanley boosts stake in axis capital holdings limited axs morgan stanley has  million position in ruth’s hospitality group inc nasdaqruth paramount gold nevada corp nysepzg upgraded by zacks investment research to “hold” solar capital ltd nasdaqslrc to release quarterly earnings on tuesday thrivent financial for lutherans has  position in worthington industries inc wor synacor inc sync set to announce quarterly earnings on tuesday encana corp eca lifted to outperform at altacorp capital advanced micro devices inc nasdaqamd earns “hold” rating from summit redstone total system services inc nysetss shares sold by teachers advisors llc teachers advisors llc has  million stake in koppers holdings inc kop cys investments inc cys stake maintained by wellington management group llp wellington management group llp has  stake in chicago bridge  iron company nv nysecbi teachers advisors llc raises position in biorad laboratories inc nysebio principal financial group inc has  million stake in contango oil  gas company nysemktmcf green dot corporation gdot shares bought by vanguard group inc dimensional fund advisors lp reduces stake in bwx technologies inc bwxt coherus biosciences chrs receiving somewhat positive news coverage analysis finds posted by danessa lincoln on jul th   no comments media headlines about coherus biosciences nasdaqchrs have been trending somewhat positive this week according to accern sentiment accern identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time accern ranks coverage of publiclytraded companies on a scale of  to  with scores closest to one being the most favorable coherus biosciences earned a news impact score of  on accern’s scale accern also gave press coverage about the biotechnology company an impact score of  out of  indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near term these are some of the news stories that may have effected accern sentiment’s scoring get coherus biosciences inc alerts coherus biosciences to report second quarter  financial results on august th – globenewswire press release globenewswirecom coherus biosciences to report second quarter  financial results on august th – nasdaq nasdaqcom market scope tracking shares of coherus biosciences inc nasdaqchrs – jonesboro recorder jonesbororecordercom trading updates on shares of coherus biosciences inc chrs – berry recorder berryrecordercom coherus biosciences nasdaq chrs opened at  on tuesday coherus biosciences has a  week low of  and a  week high of  the firm’s market capitalization is  million the stock’s  day moving average is  and its day moving average is  coherus biosciences nasdaqchrs last posted its quarterly earnings data on monday may th the biotechnology company reported  earnings per share eps for the quarter hitting analysts’ consensus estimates of  the firm had revenue of  million during the quarter coherus biosciences had a negative return on equity of  and a negative net margin of  on average equities research analysts expect that coherus biosciences will post  eps for the current year chrs has been the subject of a number of recent analyst reports maxim group set a  price target on shares of coherus biosciences and gave the stock a “buy” rating in a report on monday may th citigroup inc set a  target price on shares of coherus biosciences and gave the company a “buy” rating in a report on wednesday may th valuengine raised shares of coherus biosciences from a “strong sell” rating to a “sell” rating in a research report on friday june nd credit suisse group set a  price target on shares of coherus biosciences and gave the company a “buy” rating in a research report on monday june th finally barclays plc reaffirmed an “overweight” rating and set a  price objective on shares of coherus biosciences in a research report on sunday may st one research analyst has rated the stock with a sell rating one has issued a hold rating and nine have assigned a buy rating to the company’s stock the stock has an average rating of “buy” and a consensus target price of  warning this report was first published by markets daily and is the sole property of of markets daily if you are viewing this report on another domain it was stolen and reposted in violation of us  international trademark and copyright law the original version of this report can be accessed at httpswwwthemarketsdailycomcoherusbioscienceschrsgivendailymediaimpactratingofupdatedhtml coherus biosciences company profile coherus biosciences inc is a latestage clinical biologics platform company the company is engaged in the business of developing and commercializing biosimilar products the company’s business is organized around therapeutic franchises including oncology biosimilar candidates pegfilgrastim neulasta and bevacizumab avastin immunology antitnf biosimilar candidates etanercept enbrel and adalimumab humira ophthalmology biosimilar candidate ranibizumab lucentis and multiple sclerosis small molecule therapeutic candidate chs receive news  ratings for coherus biosciences inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for coherus biosciences inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website coherus biosciences to report second quarter  financial results on august th  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search see headlines for chrs view print version more from globenewswire coherus biosciences to report second quarter  financial results on august th coherus biosciences receives complete response letter from fda for its biologics license application for chs pegfilgrastim biosimilar candidate coherus biosciences management to present at th nasdaq omx investor program  referenced stocks chrs  rate it coherus biosciences to report second quarter  financial results on august th by globenewswire  july    am edt vote up a a a redwood city calif july   globe newswire  coherus biosciences inc nasdaqchrs today announced that its second quarter  financial results will be released after market close on monday august    starting at  pm edt coherus management will host a conference call to discuss the financial results and provide a general business update   after releasing second quarter  financial results we will post them on the coherus biosciences website at httpinvestorscoheruscom conference call informationwhen august   at  pm etdialin   toll free or   international conference id webcast  httpinvestorscoheruscomplease join the conference call at least  minutes early to register  the webcast will be archived on the coherus website about coherus biosciences inccoherus is a leading pureplay global biosimilar company that develops and commercializes highquality therapeutics for major regulated markets biosimilars are intended for use in place of existing branded biologics to treat a range of chronic and often lifethreatening diseases with the potential to reduce costs and expand patient access composed of a team of proven industry veterans with worldclass expertise in process science analytical characterization protein production sales  marketing and clinicalregulatory development coherus is positioned as a leader in the global biosimilar marketplace coherus is advancing three latestage clinical products towards commercialization chs pegfilgrastim biosimilar chs etanercept biosimilar and chs adalimumab biosimilar as well as developing a robust pipeline of future products in four therapeutic areas oncology immunology antitnf ophthalmology and multiple sclerosis for additional information please visit wwwcoheruscom contact patrick obrien senior vice president investor relations coherus biosciences incpobriencoheruscom    source coherus biosciences inc this article appears in news headlines referenced stocks chrs latest news video south florida friday morning foreca login please enable javascript to view the comments powered by realtidbits related stocks articles subscribe weyerhaeuser wy beats on q earnings lags on revenue   am validea warren buffett strategy daily upgrade report     am validea peter lynch strategy daily upgrade report     am closex signin existing nasdaqcom member log in here by signing into to the site using any of the thirdparty services above you agree to nasdaqcoms terms of use welcome back log in using your   account switch accounts highest rated articles of last week shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results spectranetics announces fda approval of stellarex™ drugcoated balloon view all highest rated todays market activity nasdaq    ▼   djia    ▲   sp     ▼   data as of jul   try for free nasdaq livequotes platform view all upcoming earnings company expected report date aapl jul   odfl jul   fb jul   tsla aug   t jul   amzn jul   vz jul   ge jul   earnings calendar closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex coherus biosciences inc  nasdaqchrs  stock quote  news  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street coherus biosciences inc chrs follow  nasdaq  health care jul    pm edt prev close  day lowhigh     wk lowhigh    avg volume k exchange nasdaq shares outstanding m market cap m eps  pe ratio na div  yield na na trade with jim cramer  days free latest news coherus biosciences to report second quarter  financial results on august th coherus biosciences stock sees short interest make  move biotech movers acceleron clovis coherus acceleron pharma clovis oncology and coherus biosciences premarket trading on tuesday jun    am edt notable monday option activity chrs blue saic looking at options trading activity among components of the russell  index there is noteworthy activity today in coherus biosciences inc  where a total volume of  contracts has been traded thus far today a contract volume which is representative of approximately  underlying shares given that every  contract represents  underlying shares that number works out to  of chrss average daily trading volume over the past month of  shares jun    pm edt biotech movers coherus xbiotech flexion coherus biosciences xbiotech and flexion therapeutics were among the biotech stock movers in premarket trading on monday jun    am edt coherus biosciences receives complete response letter from fda for its biologics license application for chs pegfilgrastim biosimilar candidate management to host a call today at  am edt to discuss fda feedback jun    am edt coherus biosciences management to present at th nasdaq omx investor program  jun    am edt first week of chrs july st options trading investors in coherus biosciences inc saw new options become available this week for the july st expiration at stock options channel our yieldboost formula has looked up and down the chrs options chain for the new july st contracts and identified one put and one call contract of particular interest may    am edt abbvie stock lower on humira patent ruling the drug is responsible for more than  of abbvies top line may    am edt coherus biosciences prevails in  ipr decision patent trial and appeal board invalidates abbvie us patent  may    pm edt first week of june th options trading for coherus biosciences chrs investors in coherus biosciences inc saw new options become available this week for the june th expiration at stock options channel our yieldboost formula has looked up and down the chrs options chain for the new june th contracts and identified one put and one call contract of particular interest may    am edt coherus biosciences reports first quarter  corporate highlights and financial results may    pm edt coherus biosciences management to present at two investor healthcare conferences in may may    am edt coherus biosciences completes patent dance exchange with amgen for neulasta biosimilar apr    am edt coherus biosciences to report first quarter  financial results on may th apr    am edt oversold conditions for coherus biosciences chrs legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful one way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the relative strength index or rsi which measures momentum on a scale of zero to  apr    pm edt coherus biosciences appoints erik wiberg as executive vice president of corporate development mar    pm edt coherus biosciences reports fourth quarter and full year  corporate highlights and financial results mar    pm edt coherus addresses trade secret action filed by amgen mar    am est statement by coherus ceo regarding biosimilars user fees mar    pm est coherus announces chs pharmacokinetic clinical bioequivalence study meets primary endpoint mar    am est coherus biosciences management to present at two investor healthcare conferences in march mar    am est coherus biosciences to report fourth quarter and full year  financial results on march th feb    pm est coherus biosciences announces new employment inducement grants feb    am est heres what blackstone bought and sold in the fourth quarter private equity firms publicly traded equity holdings are a valuable source of ideas for growth and value investors alike feb    pm est heres what blackstone and kkr are buying private equity firms publicly traded equity holdings are a valuable source of ideas for growth and value investors alike feb    pm est coherus prices public offering of common stock feb    am est coherus announces proposed public offering of common stock feb    pm est coherus biosciences files four petitions for inter partes review against abbvies humira® formulation patent  jan    pm est coherus biosciences announces positive topline week treatment phase three results for chs humira® biosimilar candidate in patients with psoriasis jan    am est next load more quant rating on  pm edt  d sell get the chrs report here from our partners medpace downgraded to sector weight from overweight at keybanc the fly  things in biotech you should learn today july   seekingalpha coherus biosciences has few more prospects in its arsenal seekingalpha coherus restructures after fda rejects marketing application for neulasta biosimilar  of workforce axed seekingalpha snippet roundup novartis enters advair generic race biogen dealt cfo blow seekingalpha coherus biosimilar knockback gives amgen neulasta on life seekingalpha  things in biotech you should learn today june   seekingalpha coherus price target lowered to  from  at credit suisse the fly analysts still bullish on coherus despite crl on chs seekingalpha amgen price target raised to  on neulasta biosimilar delay at leerink the fly coherus price target lowered to  after complete response letter at citi the fly coherus shares can hit plus on  approval says jpmorgan the fly coherus biosciences chs crl appears resolvable says cowen the fly midday gainers  losers seekingalpha coherus biosciences weakness a buying opportunity says bmo capital the fly thestreet quant rating d sell get the chrs report here trending ftc seen as set to block rite aid deal  foods to avoid if you have high cholesterol it would be crazy to clean house at wells fargo ceo says mcdonalds has a restaurant in poland that looks like the future of the golden arches amazons earnings miss but nothing can stop aws advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers microscopic polyangiitis mpa  market overview h  mentioning key vendors celltrion inc chemocentryx inc coherus biosciences inc  medgadget microscopic polyangiitis mpa – market overview h  mentioning key vendors celltrion inc chemocentryx inc coherus biosciences inc july th  htf market intelligence consulting pvt ltd releases facebook twitter google linkedin a new research document with title ‘microscopic polyangiitis mpa – pipeline review h ’  covering detailed analysis competitive landscape forecast and strategies the study covers geographic analysis and important playersvendors such as celltrion inc chemocentryx inc coherus biosciences inc etc the report will help user gain market insights future trends and growth prospects for forecast request a sample report  httpswwwhtfmarketreportcomsamplereportmicroscopicpolyangiitis summary microscopic polyangiitis mpa – pipeline review h  the latest pharmaceutical and healthcare disease pipeline guide microscopic polyangiitis mpa – pipeline review h  provides an overview of the microscopic polyangiitis mpa cardiovascular pipeline landscape microscopic polyangiitis mpa is an uncommon disease it is the result of blood vessel inflammation which can damage organ systems the area most commonly affected by mpa includes the kidneys lung nerves skin and joints symptoms include shortness of breath or cough fever loss of appetite rashes muscle andor joint pain treatment includes immunosuppressive medications report highlights the pharmaceutical and healthcare latest pipeline guide microscopic polyangiitis mpa – pipeline review h  provides comprehensive information on the therapeutics under development for microscopic polyangiitis mpa cardiovascular complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases the microscopic polyangiitis mpa cardiovascular pipeline guide also reviews of key players involved in therapeutic development for microscopic polyangiitis mpa and features dormant and discontinued projects the guide covers therapeutics under development by companies universities institutes the molecules developed by companies in phase iii and preclinical stages are  and  respectively microscopic polyangiitis mpa cardiovascular pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage the guide is built using data and information sourced from the proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis scope – the pipeline guide provides a snapshot of the global therapeutic landscape of microscopic polyangiitis mpa cardiovascular – the pipeline guide reviews pipeline therapeutics for microscopic polyangiitis mpa cardiovascular by companies and universitiesresearch institutes based on information derived from company and industryspecific sources – the pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages – the pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details rd brief moa  other developmental activities – the pipeline guide reviews key companies involved in microscopic polyangiitis mpa cardiovascular therapeutics and enlists all their major and minor projects – the pipeline guide evaluates microscopic polyangiitis mpa cardiovascular therapeutics based on mechanism of action moa drug target route of administration roa and molecule type – the pipeline guide encapsulates all the dormant and discontinued pipeline projects – the pipeline guide reviews latest news related to pipeline therapeutics for microscopic polyangiitis mpa cardiovascular buy this report  httpswwwhtfmarketreportcombuynowformatreport reasons to buy – procure strategically important competitor information analysis and insights to formulate effective rd strategies – recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage – find and recognize significant and varied types of therapeutics under development for microscopic polyangiitis mpa cardiovascular – classify potential new clients or partners in the target demographic – develop tactical initiatives by understanding the focus areas of leading companies – plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics – formulate corrective measures for pipeline projects by understanding microscopic polyangiitis mpa cardiovascular pipeline depth and focus of indication therapeutics – develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope – adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline companies mentioned in the report celltrion inc chemocentryx inc coherus biosciences inc sandoz international gmbh teijin pharma ltd get customization  check discount for report  httpswwwhtfmarketreportcomrequestdiscountmicroscopicpolyangiitis table of contents list of tables list of figures introduction global markets direct report coverage microscopic polyangiitis mpa – overview microscopic polyangiitis mpa – therapeutics development pipeline overview pipeline by companies products under development by companies microscopic polyangiitis mpa – therapeutics assessment assessment by target assessment by mechanism of action assessment by route of administration assessment by molecule type microscopic polyangiitis mpa – companies involved in therapeutics development celltrion inc chemocentryx inc coherus biosciences inc sandoz international gmbh teijin pharma ltd microscopic polyangiitis mpa – drug profiles avacopan – drug profile …continued view detailed table of content  httpswwwhtfmarketreportcomreportsmicroscopicpolyangiitis thanks for reading this article you can also get individual chapter wise section or region wise report version like north america europe or asia contact us craig francis pr  marketing manager saleshtfmarketreportcom ph     recent posts smart hanging robot keeps people walking during rehab new way to grow liver tissue to repair damaged organ nondestructive mass spectrometry helps identify tumor margins inside or baker’s yeast now used for drug discovery endoswab helps verify cleanliness of reusable endoscopes interviews  reviews cochlear unveils nucleus  world’s first made for iphone cochlear implant sound processor interview review of lifebeam vi headphones where artificial intelligence meets personal training hemopurifier filters ebola hep c metastatic melanoma interview with james a joyce ceo of aethlon medical podimetrics system helps prevent diabetic foot ulcers interview evidencebased diagnostics for mental health disorders interview with jack cosentino ceo of medibio at medgadget we report on the latest medical technology news interview leaders in the field and file dispatches from medical events from around the world about contact terms of service privacy submit press release advertise  medgadget llc  all rights reserved  the medical revolution will be blogged med tech that transforms the worldexclusive medgadget news in your mailbox your information will never be shared with any third party facebook twitter linkedin reddit hackernews google email coherus biosciences  a biosimilar therapeutics developer about coherus the frontier of biosimilars our scientific platform our products investors join our team ≡ about coherus the frontier of biosimilars our scientific platform our products investors join our team coherus biosciences is a leading developer of highquality biosimilar therapeutics our team is comprised of successful veterans who helped pioneer the biologic industry we have all joined together and are driven by a common mission improving patient benefit by expanding access to biologic drugs learn more biosimilar solutions biosimilar treatments are the next evolutionary step for biologic drugs which have saved lives and transformed medicine over the past three decades learn more about the promise of biosimilars robust pipeline coherus has a robust pipeline of biosimilar products including three latestage products to treat cancer autoimmune diseases and other serious disorders learn more about our products privacy policy site map contact us join our team copyright   coherus biosciences about coherus  coherus biosciences  a biosimilar therapeutics developer about coherus the frontier of biosimilars our scientific platform our products investors join our team ≡ about coherus the frontier of biosimilars our scientific platform our products investors join our team about coherus leadership team board of directors scientific advisory board commercial advisory committee biosimilar pure play coherus biosciences is a leader in developing and commercializing biosimilar drugs of the highest quality and value this important new pharmaceutical category supported by regulators in the us europe and asia is rapidly winning the trust of patients and healthcare providers we have a unique combination of intellectual assets commercial capabilities global reach and strategic focus required to successfully develop and market biosimilar drugs founded in  as a pureplay biosimilar platform company coherus is devoted to expanding patient access to these lifechanging therapeutics in major regulated markets around the world indeed we believe coherus is the only standalone biosimilars company with the insights and assets needed to succeed in this mission our platform includes worldclass capabilities in process science analytical characterization protein production and clinical and regulatory development what’s more our scientific and commercial goals are grounded in the expertise of an elite team of industry veterans supported from the outside by toptier global biopharmaceutical partners learn more about biosimilars our leadership team leaders at coherus helped develop the biologic drugs that turned biotech from a niche into mainstream medicine it’s the ideal team to lead the transition to biosimilar therapeutics view now board of directors view now scientific advisory board view now privacy policy site map contact us join our team copyright   coherus biosciences our products  coherus biosciences  a biosimilar therapeutics developer about coherus the frontier of biosimilars our scientific platform our products investors join our team ≡ about coherus the frontier of biosimilars our scientific platform our products investors join our team our products chs chs chs partnerships the coherus pipeline targets attractive markets our regulatory submission for our first product chs pegfilgrastim biosimilar was accepted by both us and eu regulatory agencies in  we are on track to filing two more applications in  candidate originator product originator approved indications preclinical phase  phase  status timing long acting gcsf pipeline candidate originator product originator approved indications preclinical phase  phase  status timing chs pegfilgrastim neulasta febrile neutropenia blamaa submitted region targeted filing us submitted eu submitted antitnf pipeline candidate originator product originator approved indications preclinical phase  phase  status timing chs etanercept enbrel ankylosing spondylitis juvenile idiopathic arthritis psoriasis pso psoriatic arthritis rheumatoid arthritis ra phase  clinical studies in psoriasis and ra underway region targeted filing eu h chs adalimumab humira ankylosing spondylitis crohns disease juvenile idiopathic arthritis psoriasis pso psoriatic arthritis rheumatoid arthritis ra ulcerative colitis hidradentis suppurativa uveitis phase  study complete phase  clinical study in psoriasis underway region targeted filing us h eu   phase  or blaenabling study  the therapeutic protein in etanercept is subject to certain originatorcontrolled united states patents expiring in  and  assuming these patents are valid and enforceable and that we would be unable to obtain a license to them we do not expect to commercialize chs in the united states prior to their expiration privacy policy site map contact us join our team copyright   coherus biosciences